December 16, 2022 — We’re zooming toward the end of 2022, so it’s hard to resist looking back to see which of the posts on ConscienHealth you read the most. We are grateful for the smart and diverse people who take the time to read what we post here. Seeing what captures your attention teaches us a thing or […]
December 15, 2022 — If nothing else, the last few years have transformed global supply chains from an arcane business concern into something that touched everyone. Setting aside toilet paper and electronics, let’s think for about moment about a supply chain that will be a problem stretching into the coming year – the supply chain for obesity care. How […]
December 10, 2022 — In a perverse way, there might be some good news in the current frothy coverage about new medicines for obesity and diabetes. We are a bit fed up with nonsense about who “deserves” access to care with drugs like semaglutide. But it does serve to highlight some of the usually hidden biases about treating obesity. […]
November 20, 2022 — Fed up. That’s where we are with stories about how people taking semaglutide for obesity are keeping people with diabetes from getting an adequate supply of the drug they need. Fed up, because it’s a stealthy way of expressing implicit bias against people living with obesity. The subtext is that those people don’t really need […]
November 7, 2022 — There’s a clue in the strained supply of new obesity and diabetes meds that most everyone is missing. For more than a year now, Novo Nordisk has been unable to produce and distribute an adequate supply of semaglutide in the form of Wegovy for the treatment of obesity. This has knock-on effects. So supply of […]
November 1, 2022 — Today marks the actual opening of ObesityWeek 2022 in San Diego. So to help you wade through the many hundreds for research studies being presented this week, here is a list of the top ten abstracts at ObesityWeek. Make no mistake. This is a highly subjective list, but it’s ours. Every one of you reading […]
June 24, 2022 — For decades now, Lee Kaplan and Caroline Apovian have led what was known as the Blackburn Course in Obesity Medicine every year at Harvard in June. This year, the name of the course has changed to Obesity Treatment 2022. It has moved to the Dartmouth Geisel School of Medicine, where Richard Rothstein has joined Kaplan […]
June 5, 2022 — This is what you might call a clean sweep. At the Scientific Sessions of the ADA and in NEJM yesterday, researchers unveiled detailed data on tirzepatide for obesity. When Lilly gave us a peek at these data a month ago, “Wow!” was our response. With the full details in view and peer reviewed, we tend […]
May 21, 2022 — Competition can be a great thing. In the past few weeks we’ve been hearing a lot about tirzepatide. The FDA just approved it for treating type 2 diabetes, hailing it as an important advance. Tirzepatide for obesity is a couple of years away, but the initial results of pivotal studies have been extremely impressive. So […]
May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]
